In a phase 1 double-blind randomized study, in which participants either received LY3298176 or a placebo, Coskun et al
Within 6 months after the first COVID-19 symptom, almost a third of COVID-19 survivors had a neuropsychiatric diagnosis such as insomnia, anxiety and depression [24]
They reduce blood glucose by stimulating insulin release, suppressing glucagon, and slowing gastric emptying, often lowering appetite as a downstream effect
Microbiology 165 , 492499 (2019)
Novo Nordisk has a high-dose version of Wegovy that is also on FDA fast track
Additionally, it is vital to question if it is good to invest $15,000 annually in medication for weight loss when diabetes disproportionately impacts lower-income individuals